Scancell Holdings plc (FRA:SCP)

Market Cap	134.55M
Revenue (ttm)	5.54M
Net Income (ttm)	-14.42M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	18,484
Open	0.0800
Previous Close	0.0805
Day's Range	0.0800 - 0.0800
52-Week Range	0.0550 - 0.1490
Beta	n/a
RSI	51.35
Earnings Date	Jan 23, 2026

About Scancell Holdings

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 60
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: SCP

Financial Performance

Financial numbers in GBP